Eur Heart J 2022 Jan 13. Epub 2022 Jan 13.
Department of Internal Medicine, County Hospital Bregenz, Carl-Pedenz-Strasse 2, A-6900 Bregenz, Austria.
Metabolites 2022 Jan 12;12(1). Epub 2022 Jan 12.
Department of Cardiology, University Hospital Leipzig, 04103 Leipzig, Germany.
The last decades of research in cardiovascular prevention have been characterized by successful bench-to-bedside developments for the treatment of low-density lipoprotein (LDL) hypercholesterolemia. Recent examples include the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) with monoclonal antibodies, small interfering RNA and antisense RNA drugs. The cumulative effects of LDL cholesterol on atherosclerosis make early, potent, and long-term reductions in LDL cholesterol desirable-ideally without the need of regular intake or application of medication and importantly, without side effects. Read More
Psychopharmacology (Berl) 2022 Jan 14;239(1):83-91. Epub 2022 Jan 14.
National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Rationale: It is controversial whether dyslipidemia induced by antipsychotics in schizophrenia patients is due to weight gain or direct effects of drug treatment. However, recent evidence showed that olanzapine can cause acute dyslipidemia independent of weight change, and the underlying mechanism remains unclear.Objective: To study the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in olanzapine-induced dyslipidemia, we analyzed in schizophrenic patients and in experimental models involving mice and cells to understand the mechanism. Read More
Nutrients 2021 Dec 31;14(1). Epub 2021 Dec 31.
Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20133 Milan, Italy.
Background: Dyslipidaemias, particularly elevated plasma low-density lipoprotein cholesterol (LDL-C) levels, are major risk factors for cardiovascular disease (CVD). Besides pharmacological approaches, a nutritional strategy for CVD prevention has gained increasing attention. Among functional foods, the hypocholesterolemic properties of soy are driven by a stimulation of LDL-receptor (LDL-R) activity. Read More
Front Biosci (Landmark Ed) 2021 12;26(12):1453-1463
Department of Neuroscience, Functional Pharmacology Unit, Uppsala Biomedical Centre (BMC), Uppsala University, 75124 Uppsala, Sweden.
Importance: Statins have been linked to an increased risk for insomnia, but the literature is controversial. Moreover, it is unknown, if the potential effects are directly related to the inhibition of the statin target HMGCR, the subsequently lowered cholesterol levels, or other off-target effects of statins.Aims: To investigate the association of statin treatment and genetic proxies of cholesterol lowering drugs with the risk for insomnia and chronotype in a large population-based cohort. Read More